Genomic Testing

FOUNDATIONONE®CDx

Our assay for solid tumours including but not limited to: Non-Small Cell Lung Cancer (NSCLC), Colorectal, Breast, Ovarian, and Melanoma

USES

NSCLC, CRC, Melanoma, and other solid tumours
SAMPLE TYPE

Formalin-fixed, Paraffin-embedded (FFPE) tissue
RESULTS EXPECTED

2 weeks

What is FoundationOne® CDx?

FoundationOne CDx is a validated Comprehensive^† Genomic Profile that interrogates the entire coding sequence of 324 cancer-related genes plus select introns from 36 genes often rearranged or altered in solid cancers.¹

Overview

FoundationOne CDx

A single assay that detects 4 classes of genomic alterations required to comprehensively profile a tumour.¹
Targets the entire coding regions of >300 cancer-related genes and select introns of 36 genes frequently rearranged in cancer.¹
Quantify emerging genomic signatures, Tumour Mutational Burden (TMB) and Microsatellite Instability (MSI), which may represent highly immunogenic tumours.^2,3

Gene List →

Patients who may benefit from FoundationOne CDx

FoundationOne CDx is a Comprehensive^† Genomic Profiling service that helps physicians identify potential next steps for patients with cancer by identifying the molecular growth drivers of their cancers.

Patients newly diagnosed with Stage IV rare (or uncommon) solid tumours for whom very limited or no systemic treatment exists in clinical care guidelines and/or pathways
Patients newly diagnosed with aggressive Stage IV solid tumours which have a poor prognosis, very limited response to standard of care, and a high prevalence of actionable genomic alterations
Patients newly diagnosed with carcinoma of unknown primary origin (CUP) or primary anatomic site
Patients with Stage IV solid tumours who have exhausted established guideline‐driven systemic therapy and requisite molecular testing but who maintain adequate functional status
Patients diagnosed with solid tumours whose available biopsy sample proves insufficient to complete requisite molecular testing or whose only specimen was obtained via fine needle aspiration, thoracentesis, paracentesis, or endobronchial ultrasound, thereby placing the patient at risk for additional comorbid procedure(s) to obtain additional tissue

Order FoundationOne CDx

We provide physicians with several options for ordering FoundationOne CDx for patients including fax, and phone. Healthcare providers must first complete a test requisition form to start the process and can expect results within 2 weeks from the time a tissue specimen is received at the lab location.

Patients

FoundationOne CDx is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationOne CDx testing.

Download Patient Brochure

Health Care Practitioners

FoundationOne CDx can be ordered by fax, or by phone. Please review and complete the provider resources before ordering.

Order Now

Provider Resources

Questions? We’re here to help.

† Comprehensive Genomic Profiling with FoundationOne CDx involves:

Next generation sequencing of the 324 cancer-related genes known to be clinically relevant to solid tumours
Uniform coverage across the entire coding sequence of each gene plus select introns from 36 genes frequently rearranged in cancer
Use of hybrid-capture technology to identify base substitutions, insertions/deletions, copy number alterations and rearrangements

Canadian Cancer Society website at Cancer.ca Available at: http://www.cancer.ca/en/cancer-information/cancer-101/what-is-cancer/ Accessed on: May 18, 2018.
Chalmers, Zachary R. et al. “Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumour Mutational Burden.” Genomic Medicine 9 (2017): 34. PMC. Web. 20 Mar. 2018.
Xiao, Yanping, and Gordon J. Freeman. “The Microsatellite Instable (MSI) Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy.” Cancer discovery 5.1 (2015): 16-18. PMC. Web. 21 Mar. 2018.